Figure 3.

Kaplan-Meier survival analysis of 14-3-3σ expression in the testing set and overall patients. (A) Higher 14-3-3σ expression was closely correlated with poor overall survival and (B) progression-free survival in the testing set. (C) Patients with higher 14-3-3σ expression also acquired an inferior overall survival and (D) progression-free survival in overall patients. In the testing set and overall patients, the median duration of overall survival for patients with low and high expression of 14-3-3σ was 73.0 VS. 17.0 months (p < 0.001) and 73.0 VS. 14.0 months (p < 0.001), respectively.

Zhou et al. BMC Cancer 2011 11:397   doi:10.1186/1471-2407-11-397
Download authors' original image